Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Depatureaux A, Leoz M, Le Moal G, Pathé JP, Pavie J, Batisse D, Daneluzzi V, Genet P, Gerard L, Lascaux-Cametz AS, Lambolez T, Chennebault JM, Plantier JC.
Depatureaux A, et al.
J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):e1-3. doi: 10.1097/QAI.0b013e31826327c4.
J Acquir Immune Defic Syndr. 2012.
PMID: 22918125
No abstract available.